Stock Ratings / Health Care / ANVS / forecast

BMEA (40) DWTX (41) GRCE (35) ATHE (58) ⌘ Pro Terminal →

Annovis Bio Inc. (ANVS) 12-Month Stock Forecast & Price Target Cone

$1.02 0.00% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.02

Annovis Bio Inc. (ANVS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $43.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.02 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANVS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ANVS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 51.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.21-18.2% Next Q

Q2 (-2Q)

Grade D$0.99+1% Next Q

Q3 (-1Q)

Grade D$1.00+2% Next Q

Current

Grade D-$1.02-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ANVS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ANVS currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.26) and Max Pain ($1.07) forces dealer call-delta covering toward $5.78.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANVS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ANVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ANVS Position Size: $10,000

Shares at $1.02: 9803.9 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.73

$7,157

$-2,843 (-28.4%)

12M Consensus BaseTarget $0.94

$9,216

$-784 (-7.8%)

12M Bull Case BreakoutTarget $5.78

$56,667

+$46,667 (+466.7%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$1	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$5	69%	B
JP MorganUS Large-Cap Research	SELL	$1	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANVS)

✓Walkthrough of ANVS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.22%▼ DESCENDING CHANNEL

2026-10-30O $1.02H $1.17L $1.01C $1.02VOL 1.49M

RES: $1.55SUP: $0.72SMA50: $1.26SMA200: $1.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANVS Butterfly Map → + Track ANVS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANVS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANVS)

Health Care Rank #650 of 1016 ⚔️ BMEA vs ANVS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANVS vs. BMEA, DWTX, GRCE, ATHE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Annovis Bio Inc. (ANVS) ranks #650 by composite RQD confidence (40/100, grade D-) and #767 by equity capitalization ($43.5M). Within this direct 5-issuer industry benchmark cohort, ANVS leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with ANVS at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANVS ACTIVE Annovis Bio Inc.	D-	40/100	—	—	-35.0%	0.00%	$43.5M	Benchmark Subject
BMEA Biomea Fusion Inc.	D-	40/100	—	—	-35.0%	-3.84%	$45.1M	/bmea-vs-anvs →
DWTX Dogwood Therapeutics Inc.	D-	41/100	—	—	-32.3%	-0.81%	$41.8M	/dwtx-vs-anvs →
GRCE Grace Therapeutics Inc.	D-	35/100	—	—	-18.9%	-3.48%	$40.8M	/grce-vs-anvs →
ATHE Alterity Therapeutics Limited	D+	58/100	—	—	—	+2.93%	$40.7M	/athe-vs-anvs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001477845

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Annovis Bio Inc. (ANVS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$28.9M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-17.0% YoY). On the balance sheet, ANVS closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$28.9M	-$25.6M	-$25.6M	$21.1M	—
FY2024 (FY)	2024-12-31	$0	-$24.6M	-$21.9M	-$21.9M	$13.9M	—
FY2023 (FY)	2023-12-31	$0	-$56.2M	-$40.0M	-$40.0M	—	—

3. ANVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Annovis Bio Inc. (NYSE: ANVS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.02 (0.00% 1D, market cap $43.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ANVS ranks #650 in composite RQD confidence.

How does ANVS compare to BMEA and DWTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANVS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $45.1M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -32.3%, cap $41.8M). Among the 5-stock peer group, ANVS leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANVS?

Per ANVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001477845), Annovis Bio Inc. generated $0 in revenue, -$28.9M in net income, and -$25.6M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANVS trading relative to its 50-day, 200-day, and 52-week technical levels?

ANVS last traded at $1.02 (0.00% on volume of 1,482,588 shares), positioning the stock -19.05% below its 50-day simple moving average ($1.26) and -46.87% below its 200-day simple moving average ($1.92). Across its 52-week range of $0.93 to $5.50, ANVS sits at the 2.0% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.15).

ANVS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ANVS's 12-month stock price target?

Annovis Bio Inc. (ANVS) carries a 12-month consensus base price target of $0.94 (-7.8% from $1.02), with a bull-case target of $5.78 and a bear-case floor of $0.73.

Is ANVS stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ANVS D- (Sell — SELL) with an RQD Confidence score of 40/100.

Direct Sub-Reports: ANVS RQD Cockpit ANVS 12M Forecast ANVS Earnings & Move ANVS Dividends & DRIP ANVS Insiders & 13F ANVS Whale Options ANVS Profit Sankey ANVS News & Why